Hepatitis B immune globulin

Drugs of Today

Volumn 43, Issue 6, 2007, Pages 379-394

  Habib, Shahid ^a   Shaikh, Obaid S ^b,c  

^a Center for Liver Diseases   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIHISTAMINIC AGENT; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; PARACETAMOL; PETHIDINE; RECOMBINANT HEPATITIS B VACCINE; THIOMERSAL;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG COST; DRUG MECHANISM; DRUG MONITORING; ENVIRONMENTAL EXPOSURE; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; LIVER TRANSPLANTATION; NONHUMAN; RECURRENT INFECTION; REINFECTION; REVIEW; SINGLE DRUG DOSE; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT INDICATION; VACCINATION; VIRION; VIRUS PARTICLE;

DISEASE TRANSMISSION, VERTICAL; DRUG INTERACTIONS; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; PREGNANCY; RECURRENCE;

EID: 34547761311     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.6.1050792     Document Type: Review

References (85)

1. Chung, H.T., Lee, J.S., Lok, A.S. Prevention of post-transfusion hepatitis B and C by screening for antibody to hepatitis C virus and antibody to HBcAg. Hepatology 1993, 18: 1045-9.
2. Schreiber, G.B., Busch, M.P., Kleinman, S.H., Korelitz, J.J. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996, 334: 1685-90.
3. De Feo, T.M., Poli, F., Mozzi, F., Moretti, M.P., Scalamogna, M. Collaborative kidney, liver and heart North Italy transplant program study groups. Risk of transmission of hepatitis B virus from anti-HBc positive cadaveric organ donors: A collaborative study. Transplantation Proc 2005, 37: 1238-9.
4. Mitsui, T., Iwano, K., Suzuki, S. et al. Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: Comparison with immune globulin without vaccine in historical controls. Hepatology 1989, 10: 324-7.
5. Andre, F.E., Zuckerman, A.J. Review: Protective efficacy of hepatitis B vaccines in neonates. J Med Virol 1994, 44: 144-51.
6. Roumeliotou-Karayannis, A., Papaevangelou, G., Tassopoulos, N., Richardson, S.C., Krugman, S. Post-exposure active immunoprophylaxis of spouses of acute viral hepatitis B patients. Vaccine 1985, 3: 31-4.
7. Grady, G.F., Lee, V.A., Prince, A.M. et al. Hepatitis B immune globulin for accidental exposures among medical personnel: Final report of a multicenter controlled trial. J Infect Dis 1978, 138: 625-38.
8. Seeff, L.B., Wright, E.C., Zimmerman, H.J. et al. Type B hepatitis after needle-stick exposure: Prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med 1978, 88: 285-93.
9. Redeker, A.G., Mosley, J.W., Gocke, D.J., McKee, A.P., Pollack, W. Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis. N Engl J Med 1975, 293: 1055-9.
10. Perrillo, R.P., Campbell, C.R., Strang, S., Bodicky, C.J., Costigan, D.J. Immune globulin and hepatitis B immune globulin. Prophylactic measures for intimate contacts exposed to acute type B hepatitis. Arch Intern Med 1984, 144: 81-5.
11. Centers for Disease Control and Prevention (CDC). Program to prevent perinatal hepatitis B virus transmission in a health-maintenance organization - Northern California, 1990-1995. MMWR Morb Mortal Wkly Rep. 1997, 46: 378-80.
12. Wahl, M., Iwarson, S., Snoy, P., Gerety, R.J. Failure of hepatitis B immune globulin to protect against experimental infection in chimpanzees. J Hepatol 1989, 9: 198-203.
13. Winsnes, R., Siebkem J.C. Efficacy of post-exposure prophylaxis with hepatitis B immunoglobulin in Norway. J Infect 1986, 12: 11-21.
14. Centers for Disease Control and Prevention (CDC). Updated U.S. public health service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recom mendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 2001, 50 (No. RR-11): 1-54.
15. Grady, G.F. Viral hepatitis: Passive prophylaxis with globulins - State of the art in 1978. In: Vyas, G.N., Cohen, S.N., Schmid, R. (Eds.). Viral hepatitis: A contemporary assessment of etiology, epidemiology, pathogenesis, and prevention. Franklin Institute Press, Philadelphia 1978, 467-76.
16. Beasley, R.P., Stevens, C.E. Vertical transmission of HBV and interruption with globulin. In: Vyas, G.N., Cohen, S.N., Schmid, R. (Eds.). Viral hepatitis: A contemporary assessment of etiology, epidemiology, pathogenesis, and prevention. Franklin Institute Press, Philadelphia, 1978, 333-45.
17. Szmuness, W., Stevens, C.E., Harley, E.J. et al. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980, 303: 833-41.
18. Centers for Disease Control and Prevention (DC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP); Part 1: Immunization of infants, children, and adolescents. MMWR Morb Mortal Wkly Rep 2005, 54 (No. RR-16): 1-23.
19. Zanetti, A.R., Dentico, P., Del Vecchio Blanco, C. et al. Multicenter trial on the efficacy of HBIG and vaccine in preventing perinatal hepatitis B: Final report. J Med Virol 1986, 18: 327-34.
20. Foschini, M., De Toni, A., Padula, D. et al. Prevention of perinatally transmitted hepatitis B virus infection by hepatitis B immunoglobulin immunoprophylaxis: An account of 201 newborn babies of hepatitis Bs antigen carrier mothers. J Pediatr Gastroenterol Nutr 1985, 4: 523-7.
21. Beasley, R.P., Hwang, L.Y. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state: Initial report of a randomised double-blind placebo-controlled trial. Lancet 1981, 2: 388-93.
22. Beasley, R.P., Hwang, L.Y., Stevens, C.E. et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepati tis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983, 3: 135-41.
23. Delage, G., Remy-Princem S., Montplaisirm S. Combined active-passive immunization against the hepatitis B virus: Five-year follow-up of children born to hepatitis B surface antigen-positive mothers. Pediatr Infect Dis J 1993, 12: 126-30.
24. Margolis, H.S., Coleman, P.J., Brown, R.E., Mast, E.E., Sheingold, S.H., Arevalo, J.A. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995, 274: 1201-8.
25. O'Grady, J.G., Smith, H.M., Davies, S.E. et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992, 14: 104-11.
26. Todo, S., Demetris, A.J., Van Thiel, D. et al. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991, 13: 619-26.
27. Lucey, M.R., Graham, D.M., Martin, P. et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992, 33: 1390-6.
28. Samuel, D., Muller, R., Alexander, G. et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993, 329: 1842-7.
29. McMillan, J.S., Shaw, T., Angus, P.W. et al. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995, 22: 36-43.
30. Tur-Kaspa, R., Shaul, Y., Moore, D.D. et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988, 167: 630-3.
31. Omata, M. Significance of extrahepatic replication of hepatitis B virus. Hepatology 1990, 12: 364-6.
32. Marzano, A., Gaia, S., Ghisetti, V. et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005, 11: 402-9.
33. Davies, S.E., Portmann, B.C., O'Grady, J.G. et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991, 13: 150-7.
34. Wachs, M.E., Amend, W.J., Ascher, N.L. et al. The risk of transmission of hepatitis B from HBsAg-, HBcAb+, HBIgM- organ donors. Transplantation 1995, 59: 230-4.
35. Prieto, M., Gomez, M.D., Berenguer, M. et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001, 7: 51-8.
36. Munoz, S.J. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002, 8 (Suppl. 1): S82-7.
37. Chazouilleres, O., Mamish, D., Kim, M. et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994, 343: 142-6.
38. Dickson, R.C., Everhart, J.E., Lake, J.R. et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997, 113: 1668-74.
39. Huang, E.J., Wright, T.L., Lake, J.R. et al. Hepatitis B and C coinfections and persistent hepatitis B infections: Clinical outcome and liver pathology after transplantation. Hepatology 1996, 23: 396-404.
40. Abdelmalek, M.F., Pasha, T.M., Zein, N.N. et al. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl 2003, 9: 1253-7.
41. Kim, W.R., Poterucha, J.J., Kremers, W.K. et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004, 10: 968-74.
42. Muller, R., Gubernatis, G., Farle, M. et al. Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991, 13: 90-6.
43. Samuel, D., Bismuth, A., Mathieu, D. et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991, 337: 813-5.
44. Pruett, T. Indefinite passive immunization after liver transplantation for hepatitis B. Liver Transpl 2002, 8 (Suppl. 1): S88-9.
45. Steinmuller, T., Seehofer, D., Rayes, N. et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002, 35: 1528-35.
46. McGory, R.W., Ishitani, M.B., Oliveira, W.M. et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996, 61: 1358-64.
47. Konig, V., Hopf, U., Neuhas, P. et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994, 58: 553-9.
48. Sawyer, R.G., McGory, R.W., Gaffey, M.J. et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998, 227: 841-50.
49. Naoumov, N.V., Lopes, A.R., Burra, P. et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001,34: 888-94.
50. Papatheodoridis, G.V., Sevastianos, V., Burroughs, A.K. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003, 3: 250-8.
51. Manzarbeitia, C., Reich, D.J., Ortiz, J.A., Rothstein, K.D., Araya, V.R., Munoz, S.J. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002, 8: 556-61.
52. Dodson, S.F., Bonham, C.A., Geller, D.A., Cacciarelli, T.V., Rakela, J., Fung, J.J. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999, 68: 1058-61.
53. Yu, A.S., Vierling, J.M., Colquhoun, S.D. et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001, 7: 513-7.
54. Mutimer, D. Positive suggestions about the anti-HBc positive donor. Gut 2002, 50: 7-8.
55. Roque-Afonso, A.M., Feray, C., Samuel, D. et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors. Gut 2002, 50: 95-9.
56. Uemoto, S., Sugiyama, K., Marusawa, H. et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998, 65: 494-9.
57. Yen, R.D., Bonatti, H., Mendez, J., ArandaMichel, J., Satyanarayana, R., Dickson, R.C. Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006, 6: 1077-83.
58. Fabrega, E., Garcia-Suarez, C., Guerra, A. et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: A new approach. Liver Transpl 2003, 9: 916-20.
59. Suehiro, T., Shimada, M., Kishikawa, K. et al. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int 2005, 25: 1169-74.
60. de Villa, V.H., Chen, Y., Chen, C. Hepatitis B core antibody-positive grafts: Recipient's risk. Transplantation 2003, 75 (Suppl. 3): S49-53.
61. Samuel, D. Liver transplantation and hepatitis B virus infection: The situation seems to be under control, but the virus is still there. J Hepatol 2001, 34: 943-5.
62. Loss, G.E. Jr., Mason, A.L., Nair, S. et al. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl 2003, 9: 1258-64.
63. Nery, J.R., Nery-Avila, C., Reddy, K.R. et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003, 75: 1179-86.
64. Holt, D., Thomas, R., Van Thiel, D., Brems, J.J. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002, 137: 572-5.
65. Chen, Y.S., Wang, C.C., de Villa, V.H. et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002, 16: 405-9.
66. Di Paolo, D., Tisone, G., Piccolo, P., Lend, I., Zazza, S., Angelico, M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamuvidine: A highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004, 77: 1203-8.
67. Carman, W.F., Trautwein, C., Van Deursen, F.J. et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996, 24: 489-93.
68. Hawkins, A.E., Gilson, R.J., Gilbert, N. et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 1996, 24: 8-14.
69. Ghany, M,G,, Ayola, B., Villamil, F.G. et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998, 27: 213-22.
70. Protzer-Knolle, U., Naumann, U., Bartenschlager, R. et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998, 27: 254-63.
71. Curry, M.P. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 2004, 78: 955-63.
72. Schilling, R., Ijaz, S., Davidoff, M. et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003, 77: 8882-92.
73. Lok, A.S.F. Characteristics of the hepatitis B virus and pathogenesis of infection. Uptodate 2006, Version 14.3. Available at: http://www.uptodate.com. Accessed October 2006.
74. Vianna, C.O.A., da Silva e Mouta Júnior, S., Martins, M.G.T. et al. Evaluation of murine monoclonal antibodies targeting different epitopes of the hepatitis B virus surface antigen by using immunological as well as molecular biology and biochemical approaches. J Immunol Methods 2006, 313: 38-47.
75. Teo, E., Lok, A.S.F. Hepatitis B virus vaccination. Uptodate 2006, Version 14.3. Available at: http://www.uptodate.com. Accessed October 2006.
76. Hong, H.J., Ryu, C.J., Hur, H. et al. In vivo neutralization of hepatitis B virus infection by an anti-pre-S1 humanized antibody in chimpanzees. Virology 2004, 318: 134-41.
77. Maeng, C.Y., Ryu, C.J., Grippon, P., Guguen-Guillouzo, C., Hong, H.J. Fine mapping of vi rus-neutrallzing epitopes on hepatitis B virus pre-S1. Virology 2000, 270: 9-16.
78. Galun, E., Eren, R., Safadi, R. et al. Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties. Hepatology 2002, 35: 673-9.
79. Adler, R., Safadi, R., Caraco, Y. et al. Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Hepatology 1999, 29: 1299-305.
80. Fung, J., Ostberg, L., Shapiro, R. et al. Human monoclonal antibody against hepatitis B surface antigen in preventing recurrent hepatitis B following liver transplantation. In: Hollinger, F.B., Lemon, S.M., Margolis, H.S. (Eds.). Viral hepatitis and liver disease. Williams & Wil-kins, Baltimore, 1991, 651.
81. McMahon, G., Ehrlich, P.H., Moustafa, Z.A. et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992, 15: 757-66.
82. Yao, F.Y., Osorio, R.W., Roberts, J.P. et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999, 5: 491-6.
83. Terrault, N.A., Zhou, S., Combs, C. et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996, 23: 1327-33.
84. Lowell, J.A., Burgess, S., Shenoy, S. et al. Mercury poisoning associated with high-dose hepatitis-B immune globulin administration after liver transplantation for chronic hepatitis B. Liver Transpl Surg 1996, 2: 475-8.
85. Villamil, F.G., Vierling, J.M. Recurrence of viral hepatitis after liver transplantation: Insights into management. Liver Transpl Surg 1995, 1 (Suppl. 1): 89-99.